Bicara Therapeutics (NASDAQ:BCAX) Trading 5.5% Higher – Here’s What Happened

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) were up 5.5% on Monday . The stock traded as high as $18.63 and last traded at $18.55. Approximately 60,256 shares changed hands during trading, a decline of 86% from the average daily volume of 425,623 shares. The stock had previously closed at $17.59.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on BCAX shares. Stifel Nicolaus began coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They issued a “buy” rating and a $47.00 target price on the stock. Morgan Stanley began coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 price objective for the company. Cantor Fitzgerald assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued an “overweight” rating for the company. RODMAN&RENSHAW raised shares of Bicara Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 5th. Finally, Rodman & Renshaw started coverage on shares of Bicara Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price objective for the company. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $43.00.

Bicara Therapeutics Stock Up 2.0 %

The company has a 50-day moving average of $20.79.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). Research analysts expect that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Institutional Trading of Bicara Therapeutics

Large investors have recently added to or reduced their stakes in the business. Barclays PLC acquired a new position in shares of Bicara Therapeutics in the 3rd quarter valued at $255,000. Teachers Retirement System of The State of Kentucky purchased a new position in Bicara Therapeutics during the 3rd quarter worth approximately $358,000. Geode Capital Management LLC acquired a new stake in shares of Bicara Therapeutics in the third quarter worth $1,239,000. Jane Street Group LLC purchased a new position in shares of Bicara Therapeutics during the third quarter valued at $309,000. Finally, Wellington Management Group LLP acquired a new stake in Bicara Therapeutics during the 3rd quarter worth about $19,458,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.